The final analysis of the KEYNOTE-811 trial presented at ESMO24

ESMO shared on LinkedIn:

“As presented at ESMO24, the final analysis of the KEYNOTE-811 trial reports statistically significant improvement in OS with first-line pembrolizumab versus placebo added to trastuzumab and chemotherapy in patients with unresectable, HER2-positive metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma, regardless of PD-L1 status.

For Filippo Pietrantonio, the clinically meaningful data suggest that the immunotherapy combination will now become the standard-of-care comparator arm for future first-line phase III Clinical Trials in this setting.

Read the full article on the ESMO Daily Reporter.”

Source: ESMO/LinkedIn

More posts featuring ESMO24 on oncodaily.com